CFGI’s Capital Markets team supported atai Life Sciences B.V. (Nasdaq: ATAI) with their Initial Public Offering. On June 17, 2021, the offering was upsized to 15,000,000 common shares at a price to the public of $15.00 per share, with a 30-day underwriters’ option to purchase an additional 2,250,000 common shares.The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, were $225.0 million. The shares began trading June 18, 2021, on the Nasdaq Global Market under the ticker symbol “ATAI,” and the offering closed on June 22, 2021.
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. atai is headquartered in Berlin, with offices in New York and London.
The CFGI team was led by Chris Nyers (Accounting Advisory), Lindsi Scanlan (Accounting Advisory) and Carla Amaning (Capital Markets).
For further information on the offering, please read atai’s press release.
